Centivax
Accelerating the world's transition to a post-pathogen humanity.
San Francisco, United States · Founded 2019 · $92.0M raised
- Headquarters
- San Francisco, California
- Employees
- 11–50
- Founded
- 2019
- Business Model
- B2B
- Website
- centivax.com
- Total Funding
- $92.0M
- Last Round
- $37.0M Series BMar 2026
- Rounds
- 3
About
Centivax is a clinical-stage universal immunity company deploying a proprietary computational immune-engineering platform to develop broad-spectrum vaccines and therapeutic antibodies. Founded in 2019 by computational immunologist Jacob Glanville, the company's lead program is a universal influenza vaccine currently in Phase 1 clinical trials, which was awarded a Gates Foundation Grand Challenge. Centivax is also developing universal vaccines for other pathogens and antivenom therapies. The company is headquartered in South San Francisco, California and has raised over $55 million in funding.
Summary
Centivax is a Biotech company based in San Francisco, United States, founded in 2019. It has raised $92.0M in total across 3 rounds, most recently a $37.0M Series B round in Mar 2026. Investors include Structure Capital.
Tech & App Stack
1 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Mar 2026
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...